Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Frontiers in Molecular Biosciences|July 9, 2026
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinibWalid Shalata, Bilal Krayim, Asmah Miari, et al.
International Journal of Molecular Sciences|February 13, 2026
Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer PatientsAlexander Yakobson, Abed Agbarya, Yulia Dudnik, et al.
Annals of Hematology|June 10, 2021
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255KAfsar Ali Mian, Isabella Haberbosch, Hazem Khamaisie, et al.
Journal of Pain and Symptom Management|December 16, 2014
Compared perspectives of Arab patients in Palestine and Israel on the role of complementary medicine in cancer careEran Ben-Arye, Amneh M A Hamadeh, Elad Schiff, et al.
Biomedicines|March 29, 2023
Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center StudyMohammad Sheikh-Ahmad, Leonard Saiegh, Anan Shalata, et al.
International Journal of Medicinal Mushrooms|December 24, 2016
Anti-Inflammation Properties of Fruiting Bodies and Submerged Cultured Mycelia of Culinary-Medicinal Higher Basidiomycetes MushroomsRao-Chi Chien, Lan-Min Lin, Yuan-Hua Chang, et al.
Cancers|May 25, 2024
Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB StatusWalid Shalata, Natalie Maimon Rabinovich, Abed Agbarya, et al.
Journal of Clinical Medicine|November 9, 2024
Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung CancerWalid Shalata, Sameh Daher, Natali Maimon Rabinovitch, et al.
Medical Sciences (Basel, Switzerland)|September 22, 2025
Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain MetastasesWalid Shalata, Rashad Naamneh, Wenad Najjar, et al.
Journal of Clinical Medicine|May 14, 2022
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, et al.
Pageof 9